But you can't practise evidence-based medicine on a substance that has no evidence," said Phillips
We source research from peer-reviewed medical journals, top government agencies, leading academic institutions, and respected advocacy groups
[3] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH
Published clinical research has characterised the compound in controlled trials: a Phase 2 obesity trial reported dose-dependent body-weight change in the study population (Jastreboff et al., 2023), and a separate Phase 2 trial investigated the GIP/GLP-1/glucagon agonist in people with type 2 diabetes (Rosenstock et al., 2023)
Usage: Target Species: Horses, cattle, dogs, and cats Indications: Treatment and prevention of anemia due to Vitamin B12 deficiency Administration: Dosage: Horses and Cattle: 14 mL administered subcutaneously (S.C.), intramuscularly (I.M.), or intravenously (I.V.) Dogs and Cats: 0.51 mL administered S.C., I.M., or I.V